NCT03547115 2026-03-17
A Study of Voruciclib Alone or in Combination With Venetoclax in Subjects With B-Cell Malignancies or AML
MEI Pharma, Inc.
Phase 1 Terminated
Clinical Trials
11 trialsNCT04903197 2026-01-22
Study of VAY736 as Single Agent and in Combination With Select Antineoplastic Agents in Patients With Non-Hodgkin Lymphoma
Novartis
Phase 1 Terminated
NCT05336409 2025-12-18
ELiPSE-1
Century Therapeutics, Inc.
Phase 1 Terminated
NCT05673759 2025-12-16
Event-Related Potential (ERP) Components in Clinical Diagnosis
Boston University
Terminated
NCT00987428 2025-11-20
EEPAB2
Assistance Publique - Hôpitaux de Paris
Phase NA Terminated
NCT05169489 2025-10-21
A Study of bbT369 in Relapsed and/or Refractory B Cell Non-Hodgkin's Lymphoma (NHL)
Regeneron Pharmaceuticals
Phase 1 Terminated
NCT06343376 2025-08-03
Genetically Engineered Cells (EGFRt/19-28z/IL-12 CAR T Cells) for the Treatment of Relapsed or Refractory CD19+ Hematologic Malignancies
Roswell Park Cancer Institute
Phase 1 Terminated
NCT03401853 2025-07-22
Pembrolizumab With Rituximab or Obinutuzumab in Treating Patients With Relapsed or Refractory Follicular Lymphoma or Diffuse Large B Cell Lymphoma
University of Washington
Phase 2 Terminated
NCT05785715 2025-07-01
Study to Evaluate the Clinical Activity and Safety of Oral NX-13 in Moderate to Severe Ulcerative Colitis
AbbVie
Phase 2 Terminated
NCT04735471 2025-06-18
GLEAN-1
Adicet Therapeutics
Phase 1 Terminated
NCT00848328 2025-04-24
Lenalidomide and Rituximab in Treating Patients With Non-Hodgkin Lymphoma
University of California, Davis
Phase 2 Terminated